
Vera Therapeutics (VERA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-57.2M
Net Income
-51.7M
EPS (Diluted)
$-0.81
Balance Sheet Metrics
Total Assets
610.2M
Total Liabilities
75.2M
Shareholders Equity
535.0M
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
-41.2M
Free Cash Flow
-54.6M
Revenue & Profitability Trend
Vera Therapeutics Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 126.2M | 78.2M | 69.0M | 22.5M | 45.2M |
Selling, General & Administrative | 41.0M | 23.8M | 21.9M | 11.9M | 4.0M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 167.2M | 102.0M | 90.9M | 34.4M | 49.2M |
Operating Income | -167.2M | -102.0M | -90.9M | -34.4M | -49.2M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 20.7M | 8.0M | 1.8M | 15.0K | 8.0K |
Interest Expense | 7.6M | 3.8M | 992.0K | 20.0K | 166.0K |
Other Non-Operating Income | 1.9M | 1.8M | 1.1M | 1.8M | -4.1M |
Pre-tax Income | -152.1M | -96.0M | -89.1M | -32.6M | -53.4M |
Income Tax | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -152.1M | -96.0M | -89.1M | -32.6M | -53.4M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -144.4M | -92.2M | -87.3M | -34.2M | -50.0M |
EPS (Basic) | $-2.75 | $-2.25 | $-3.35 | $-2.43 | $-13.10 |
EPS (Diluted) | $-2.75 | $-2.25 | $-3.35 | $-2.43 | $-13.10 |
Basic Shares Outstanding | 55326680 | 42707072 | 26570676 | 13435706 | 4076345 |
Diluted Shares Outstanding | 55326680 | 42707072 | 26570676 | 13435706 | 4076345 |
Income Statement Trend
Vera Therapeutics Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 92.6M | 45.7M | 43.5M | 79.7M | 53.7M |
Short-term Investments | 548.2M | 115.0M | 71.2M | 0 | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 913.0K | 3.2M | 719.0K | 480.0K | 392.0K |
Total Current Assets | 651.2M | 172.0M | 125.7M | 82.5M | 54.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 960.0K | 92.0K | 51.0K | 0 | 0 |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 131.0K | 482.0K | 513.0K | 344.0K | 293.0K |
Total Non-Current Assets | 4.5M | 3.5M | 5.7M | 1.2M | 293.0K |
Total Assets | 655.7M | 175.5M | 131.4M | 83.7M | 54.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 7.7M | 11.1M | 12.0M | 1.4M | 909.0K |
Short-term Debt | 1.5M | 2.4M | 2.6M | - | 2.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 377.0K | 962.0K |
Total Current Liabilities | 25.4M | 22.3M | 25.6M | 7.7M | 2.4M |
Non-Current Liabilities | |||||
Long-term Debt | 53.2M | 51.3M | 28.6M | 4.9M | 0 |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | 1.3M | 1.6M |
Total Non-Current Liabilities | 53.2M | 51.6M | 28.9M | 6.5M | 141.5M |
Total Liabilities | 78.5M | 73.9M | 54.5M | 14.2M | 143.9M |
Equity | |||||
Common Stock | 64.0K | 44.0K | 28.0K | 21.0K | 0 |
Retained Earnings | -461.2M | -309.1M | -213.1M | -124.1M | -91.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 577.2M | 101.7M | 76.9M | 69.6M | -89.3M |
Key Metrics | |||||
Total Debt | 54.6M | 53.7M | 31.3M | 4.9M | 2.0K |
Working Capital | 625.8M | 149.7M | 100.1M | 74.8M | 51.9M |
Balance Sheet Composition
Vera Therapeutics Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -152.1M | -96.0M | -89.1M | -32.6M | -53.4M |
Depreciation & Amortization | 105.0K | -4.1M | -846.0K | 176.0K | 251.0K |
Stock-Based Compensation | 20.8M | 11.5M | 8.9M | 3.0M | 331.0K |
Working Capital Changes | -5.5M | -3.8M | 7.9M | 424.0K | 148.0K |
Operating Cash Flow | -133.9M | -90.2M | -67.3M | -25.0M | -36.0M |
Investing Activities | |||||
Capital Expenditures | -972.0K | -63.0K | -62.0K | 0 | -42.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | -703.0M | -224.9M | -148.5M | 0 | - |
Investment Sales | 279.0M | 185.6M | 78.0M | 0 | - |
Investing Cash Flow | -425.0M | -39.4M | -70.6M | -5.0M | -42.0K |
Financing Activities | |||||
Share Repurchases | -13.0K | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 24.7M | 19.8M | 4.9M | 5.6M |
Debt Repayment | - | - | - | 0 | -130.0K |
Financing Cash Flow | 593.3M | 132.5M | 99.8M | 53.3M | 85.1M |
Free Cash Flow | -135.7M | -92.2M | -67.7M | -23.7M | -34.9M |
Net Change in Cash | 34.4M | 2.9M | -38.0M | 23.3M | 49.0M |
Cash Flow Trend
Vera Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.04
Forward P/E
-7.05
Price to Book
2.99
PEG Ratio
-0.09
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-54.84%
Return on Assets
-30.24%
Financial Health
Current Ratio
17.03
Debt to Equity
16.56
Beta
1.17
Per Share Data
EPS (TTM)
$-3.59
Book Value per Share
$7.34
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
vera | 1.4B | -8.04 | 2.99 | -54.84% | 0.00% | 16.56 |
Vertex | 100.2B | 27.77 | 5.83 | 22.77% | 31.86% | 8.89 |
Regeneron | 62.9B | 14.95 | 2.06 | 15.34% | 31.37% | 9.04 |
Cg Oncology | 2.0B | -18.13 | 2.97 | -12.00% | 0.00% | 0.15 |
Adaptive | 2.0B | -12.07 | 11.04 | -57.60% | -59.07% | 121.39 |
Vericel | 1.8B | 255.21 | 5.87 | 2.59% | 2.85% | 32.74 |
Financial data is updated regularly. All figures are in the company's reporting currency.